Legend Biotech
LEGN
210 hedge funds and large institutions have $3B invested in Legend Biotech in 2025 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 71 increasing their positions, 86 reducing their positions, and 30 closing their positions.
68% more call options, than puts
Call options by funds: $27.7M | Put options by funds: $16.5M
22.49% more ownership
Funds ownership: 23.58% → 46.07% (+22%)
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
1% more funds holding
Funds holding: 207 → 210 (+3)
3% more capital invested
Capital invested by funds: $2.91B → $3B (+$96.4M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
17% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 86
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$404M |
| 2 |
DM
Deerfield Management
New York
|
+$39.5M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$32.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.2M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$192M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$94.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$63M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$59.1M |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$32.1M |
LEGN Hedge Fund Activity: Q2 2025 in Review
210 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2025, worth a combined $3B — up 3.3% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LEGN positions and 30 closed out — a net gain of 6 holders — while 71 added to existing stakes and 86 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $404M. The largest seller was T. Rowe Price Associates, cutting an estimated $192M.
- 210 institutional investors held Legend Biotech (LEGN) as of Q2 2025, up from 207 in Q1 2025.
- Funds reported $3B of Legend Biotech stock for Q2 2025, up 3.3% quarter-over-quarter.
- 36 funds opened new Legend Biotech positions in Q2 2025 and 30 closed out, a net change of +6 holders.
- The largest Legend Biotech buyer in Q2 2025 was Fidelity Investments, an estimated $404M added.
- The largest Legend Biotech seller in Q2 2025 was T. Rowe Price Associates, an estimated $192M sold.
Based on aggregated 13F filings for Q2 2025.